Arbutus Biopharma Corp (NAS:ABUS)
$ 3.34 -0.29 (-7.99%) Market Cap: 630.32 Mil Enterprise Value: 557.49 Mil PE Ratio: 0 PB Ratio: 5.22 GF Score: 60/100

Q1 2020 Arbutus Biopharma Corp Earnings Call Transcript

May 11, 2020 / 12:00PM GMT
Release Date Price: $1.44 (+6.67%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Arbutus Biopharma Corporation First Quarter 2020 Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference to your speaker today, Pam Murphy. Please go ahead, ma'am.

Pam Murphy
Arbutus Biopharma Corporation - IR Consultant

Thank you, and good morning, everyone. On the call from the Arbutus executive team are Bill Collier, President and Chief Executive Officer; Dr. Michael Sofia, Chief Scientific Officer; Dave Hastings, Chief Financial Officer; and Dr. Gaston Picchio, Chief Development Officer. Bill will begin with a summary of recent accomplishments and a review of Arbutus' corporate objectives, followed by Dr. Sofia, who will then describe the recently announced Arbutus COVID-19 research effort. Dave Hastings will then provide a review of the company's first quarter financial results, and we'll then open up the call for Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot